Intrahepatic cholangiocarcinoma (ICC), a malignant neoplasm of the biliary epithelium, is usually fatal because of difficulty in early diagnosis and lack of availability of effective therapy. The genetic mechanisms involved in the development of ICC are not well understood and only a few cytogenetic studies of ICC have been published. Recently, technique of degenerate oligonucleotide primed (DOP)-PCR comparative genomic hybridization (CGH) permits genetic imbalances screening of the entire genome using only small amounts of tumor DNA. In this study chromosomal aberrations in 33 Korean ICC were investigated by DOP-PCR CGH. The common sites of copy number increases were 20q (67%), 17 (61%), 11q11-q13 (42%), 8p12-qter (39%), 18p (39%), 15q22-qter (36%), 16p (36%), 6p21 (30%), 3q25-qter (27%), 1q41-qter (24%), and 5p14-q11.2 (24%). DNA amplification was identified in 16 carcinomas (48%). The frequent sites of amplification were 20q, 17p, 17q23-qter, and 7p. The most frequent sites of copy number decreases were 1p32-pter (21%) and 4q (21%). The recurrent chromosomal aberrations identified in this study provide candidate regions involved in the tumorigenesis and progression of ICC.
Adult ; Aged ; Bile Duct Neoplasms/*genetics ; *Bile Ducts, Intrahepatic ; Cholangiocarcinoma/*genetics ; *Chromosome Aberrations ; DNA Primers ; Female ; Gene Dosage ; Humans ; Male ; Middle Aged ; Nucleic Acid Hybridization/methods ; Oligonucleotides ; Polymerase Chain Reaction/*methods ; Research Support, Non-U.S. Gov't

To gain insight into the differential mechanism of gene promoter hypermethylation in acute and chronic leukemia, we identified the methylation status on one part of 5'CpG rich region of 8 genes, DAB2IP, DLC-1, H-cadherin, ID4, Integrin alpha4, RUNX3, SFRP1, and SHP1 in bone marrows from acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) patients. Also, we compared the methylation status of genes in AML and CML using methylation-specific PCR (MSP). The frequencies of DNA methylation of ID4, SFRP1, and SHP1 were higher in AML patients compared to those in CML patients. In contrast, no statistical difference between AML and CML was detected for other genes such as DLC-1, DAB2IP, H-cadherin, Integrin alpha4, and RUNX3. Taken together, these results suggest that these methylation-controlled genes may have different roles in AML and CML, and thus, may act as a biological marker of AML.
Adolescent ; Adult ; Aged ; CpG Islands ; *DNA Methylation ; Female ; Humans ; Inhibitor of Differentiation Proteins/*genetics/metabolism ; Intercellular Signaling Peptides and Proteins/*genetics/metabolism ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics/metabolism ; Leukemia, Myeloid, Acute/*genetics/metabolism ; Male ; Membrane Proteins/*genetics/metabolism ; Middle Aged ; Promoter Regions, Genetic ; Protein Tyrosine Phosphatase, Non-Receptor Type 6/*genetics/metabolism

To gain insight into the differential mechanism of gene promoter hypermethylation in acute and chronic leukemia, we identified the methylation status on one part of 5'CpG rich region of 8 genes, DAB2IP, DLC-1, H-cadherin, ID4, Integrin alpha4, RUNX3, SFRP1, and SHP1 in bone marrows from acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) patients. Also, we compared the methylation status of genes in AML and CML using methylation-specific PCR (MSP). The frequencies of DNA methylation of ID4, SFRP1, and SHP1 were higher in AML patients compared to those in CML patients. In contrast, no statistical difference between AML and CML was detected for other genes such as DLC-1, DAB2IP, H-cadherin, Integrin alpha4, and RUNX3. Taken together, these results suggest that these methylation-controlled genes may have different roles in AML and CML, and thus, may act as a biological marker of AML.
Adolescent ; Adult ; Aged ; CpG Islands ; *DNA Methylation ; Female ; Humans ; Inhibitor of Differentiation Proteins/*genetics/metabolism ; Intercellular Signaling Peptides and Proteins/*genetics/metabolism ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics/metabolism ; Leukemia, Myeloid, Acute/*genetics/metabolism ; Male ; Membrane Proteins/*genetics/metabolism ; Middle Aged ; Promoter Regions, Genetic ; Protein Tyrosine Phosphatase, Non-Receptor Type 6/*genetics/metabolism